NIH Director Page NIH Health Information Page NIH Impact NIH Fact Sheets NIH Social Media and Outreach
EurekAlert! - National Institutes of Health  
LINKS

Resources

 

NIH Main

 

NIH Research News

 

Funded News

 
  For News & Research
  NIH Videos
  eColumn: NIH Research Matters
  NIH News in Health
  NIH Fact Sheets
 
  Additional Resources
  NIH Home Page
 

About NIH

  NIH Health Information
  Pub Med
  MedlinePlus
  Clinical trials.gov
  More News and Events Sources
  NIH News and Events, Special Interest
 
  RSS Feed RSS Feed
  Back to EurekAlert!
 

 


Department of Health and Human Services

News from the National Institutes of Health

NIH Research News


Key: Meeting M      Journal J      Funder F

Showing releases 1-25 out of 104.

1 | 2 | 3 | 4 | 5 > >>

Public Release: 22-Oct-2014
NIH begins early human clinical trial of VSV Ebola vaccine
Human testing of a second investigational Ebola vaccine candidate is under way at the National Institutes of Health's Clinical Center. Researchers at NIAID are conducting the early phase trial to evaluate the vaccine, called VSV-ZEBOV, for safety and its ability to generate an immune system response in healthy adults who are given two intramuscular doses, called a prime-boost strategy. The Walter Reed Army Institute of Research is simultaneously testing the vaccine candidate as a single dose at its Clinical Trials Center.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Kathy Stover
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 20-Oct-2014
Translational Psychiatry
Rapid agent restores pleasure-seeking ahead of other antidepressant action
A drug being studied as a fast-acting mood-lifter restored pleasure-seeking behavior independent of -- and ahead of -- its other antidepressant effectsWithin 40 minutes after a single infusion of ketamine, treatment-resistant depressed bipolar disorder patients experienced a reversal of a key symptom -- loss of interest in pleasurable activities -- which lasted up to 14 days. Brain scans traced the agent's action to boosted activity in areas at the front and deep in the right hemisphere of the brain.
National Institute of Mental Health

Contact: Jules Asher
NIMHpress@nih.gov
301-443-4536
NIH/National Institute of Mental Health

Public Release: 17-Oct-2014
Using social media to better understand, prevent, and treat substance use
More than $11 million over three years will be used to support research exploring the use of social media to advance the scientific understanding, prevention, and treatment of substance use and addiction. The awards are funded through the Collaborative Research on Addiction at NIH, an NIH consortium involving NIAAA, NIDA and NCI.
NIH/National Institute on Alcohol Abuse and Alcoholism, NIH/National Institute on Drug Abuse, NIH/National Cancer Institute

Contact: NIDA Press Office
media@nida.nih.gov
301-443-6245
NIH/National Institute on Drug Abuse

Public Release: 15-Oct-2014
NIH grants license agreement for candidate Ebola vaccines
NIAID today announced a new license agreement aimed at advancing dual-purpose candidate vaccines to protect against rabies and Ebola viruses. The vaccines were created by scientists at NIAID and Thomas Jefferson University in Philadelphia and are being further developed through a partnership with the German pharmaceutical company IDT Biologika. The candidate vaccines now have been licensed to Exxell BIO of Saint Paul, Minnesota, which aims to advance the products through clinical testing and commercialization.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Hillary Hoffman
hillary.hoffman@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 14-Oct-2014
Journal of Neuroscience
Scientists sniff out unexpected role for stem cells in the brain
For decades, scientists thought that neurons in the brain were born only during the early development period and could not be replenished. More recently, however, they discovered cells with the ability to divide and turn into new neurons in specific brain regions. Scientists at the National Institutes of Health report that newly formed brain cells in the mouse olfactory system -- the area that processes smells -- play a critical role in maintaining proper connections.
National Institutes of Health Intramural Program

Contact: Barbara McMakin
nindspressteam@ninds.nih.gov
NIH/National Institute of Neurological Disorders and Stroke

Public Release: 8-Oct-2014
NIH funds research consortia to study more than 200 rare diseases
Physician scientists at 22 consortia will collaborate with representatives of 98 patient advocacy groups to advance clinical research and investigate new treatments for patients with rare diseases. The collaborations are made possible through awards by the National Institutes of Health -- totaling about $29 million in fiscal year 2014 funding -- to expand the Rare Diseases Clinical Research Network, which is led by NIH's National Center for Advancing Translational Sciences.
National Institutes of Health, NIH/National Center for Advancing Translational Sciences, NIH/Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH/National Cancer Institute, NIH/National Heart, Lung and Blood Institute

Contact: Bobbi Gardner
bobbi.gardner@nih.gov
301-435-0888
NIH/National Center for Advancing Translational Sciences (NCATS)

Public Release: 8-Oct-2014
Science
NIH-supported scientists unveil structure, dynamics of key HIV molecules
New research has illuminated the movement and complete structure of the spikes on HIV that the virus uses to bind to the cells it infects. This research, led by scientists at the National Institutes of Health, Weill Cornell Medical College and Yale University School of Medicine, could help advance efforts to develop HIV vaccines and treatments.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Laura S. Leifman
laura.sivitz@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 8-Oct-2014
JAMA Psychiatry
Increased health risks linked to first-episode psychosis
Many patients with psychosis develop health risks associated with premature death early in the course of their mental illness. Patients with schizophrenia are already known to have higher rates of premature death than the general population. Elevated risks of heart disease and metabolic issues such as high blood sugar in people with first episode psychosis are due to an interaction of mental illness, unhealthy lifestyle behaviors and antipsychotic medications that may accelerate these risks.
NIH/National Institute of Mental Health

Contact: Michaelle Scanlon
NIMHpress@nih.gov
301-443-4536
NIH/National Institute of Mental Health

Public Release: 8-Oct-2014
New England Journal of Medicine
Gene therapy shows promise for severe combined immunodeficiency
Researchers have found that gene therapy using a modified delivery system, or vector, can restore the immune systems of children with X-linked severe combined immunodeficiency (SCID-X1), a rare, life-threatening inherited condition that primarily affects boys.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Hillary Hoffman
hillary.hoffman@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 7-Oct-2014
JAMA
Candidate H7N9 avian flu vaccine works better with adjuvant
An experimental vaccine to protect people against H7N9 avian influenza prompted immune responses in 59 percent of volunteers who received two injections at the lowest dosage tested, but only if the vaccine was mixed with adjuvant -- substance that boosts the body's response to vaccination. Without adjuvant, immune responses produced by the investigational vaccine were minimal regardless of vaccine dosage, according to findings from a clinical trial sponsored by NIAID, part of NIH.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Anne A. Oplinger
aoplinger@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 2-Oct-2014
HHS releases 13th Report on Carcinogens
Four substances have been added in the US Department of Health and Human Services 13th Report on Carcinogens, a science-based document that identifies chemical, biological, and physical agents that are considered cancer hazards for people living in the United States. The new report includes 243 listings.
National Institute of Environmental Health Sciences, National Toxicology Program

Contact: Robin Mackar
rmackar@niehs.nih.gov
919-541-0073
NIH/National Institute of Environmental Health Sciences

Public Release: 29-Sep-2014
NIH awards 7 new vaccine adjuvant discovery contracts
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded seven research contracts to discover and characterize new adjuvants, or substances formulated as part of vaccines to enhance their protective ability.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Hillary Hoffman
hillary.hoffman@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 25-Sep-2014
NIH and VA address pain and related conditions in US military personnel and veterans
Thirteen research projects totaling approximately $21.7 million over five years will explore nondrug approaches to managing pain and related health conditions such as post-traumatic stress disorder, drug abuse, and sleep issues. The effort seeks to enhance options for the management of pain and associated problems in US military personnel, veterans, and their families. NIH's NCCAM and NIDA and the US Department of Veterans Affairs Health Services Research and Development Division provided funding for this initiative.
NIH/National Center for Complementary and Alternative Medicine, NIH/National Institute on Drug Abuse, US Department of Veterans Affairs/Health Services Research and Development Division

Contact: Katy Danielson
nccampress@mail.nih.gov
301-496-7790
NIH/National Center for Complementary and Alternative Medicine

Public Release: 24-Sep-2014
Emerging Infectious Diseases
NIH study supports camels as primary source of MERS-CoV transmission
NIH and Colorado State University scientists have provided experimental evidence supporting dromedary camels as the primary reservoir, or carrier, of Middle East respiratory syndrome coronavirus. The study, designed by scientists from CSU and NIH's National Institute of Allergy and Infectious Diseases, involved three healthy camels exposed through the eyes, nose and throat to MERS-CoV isolated from a patient. Each camel developed a mild upper respiratory tract infection consistent with what scientists have observed throughout the Middle East.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Ken Pekoc
kpekoc@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 24-Sep-2014
NIH announces network to accelerate medicines for rheumatoid arthritis and lupus
The National Institutes of Health has awarded grants to 11 research groups across the United States to establish the Accelerating Medicines Partnership in Rheumatoid Arthritis and Lupus Network.
National Institutes of Health, AbbVie, Bristol-Myers Squibb, Merck, Pfizer, Sanofi, Takeda, the Arthritis Foundation, the Lupus Foundation of America, the Lupus Research Institute/Alliance for Lupus Research, and the Rheumatology Research Foundation.

Contact: Trish Reynolds
reynoldsp2@mail.nih.gov
301-496-8190
NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases

Public Release: 23-Sep-2014
NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain
NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain
The National Institutes of Health is convening a Pathways to Prevention workshop to assess the available scientific evidence on the long-term effectiveness and potential risks of opioids for treating chronic pain. Participants will be among the nation's top experts in the field of pain control and management from around the country, as well as key NIH scientists who focus on pain related research. An impartial, independent panel will identify research gaps and future research priorities.

Contact: Deborah Langer
langerdh@od.nih.gov
301-443-4569
NIH/Office of Disease Prevention

Public Release: 23-Sep-2014
NIH funds next phase of Tissue Chip for Drug Screening program
The National Institutes of Health will award funds to support the next phase of its Tissue Chip for Drug Screening program to improve ways of predicting drug safety and effectiveness. Researchers will collaborate over three years to refine existing 3-D human tissue chips and combine them into an integrated system that can mimic the complex functions of the human body.
National Institutes of Health

Contact: Geoff Spencer
spencerg@mail.nih.gov
301-435-0888
NIH/National Center for Advancing Translational Sciences (NCATS)

Public Release: 23-Sep-2014
New supplemental awards apply sex and gender lens to NIH-funded research
The National Institutes of Health has awarded $10.1 million in supplemental funding to bolster the research of 82 grantees to explore the effects of sex in preclinical and clinical studies.
National Institutes of Health

Contact: Anne Rancourt
anne.rancourt@nih.gov
301-451-7058
NIH/Office of the Director

Public Release: 12-Sep-2014
NIH awards aim to improve understanding of cell pathways, development of new therapies
National Institutes of Health has awarded more than $64 million to six research institutions to create a database of human cellular responses, the Library of Integrated Network-based Cellular Signatures. Discovering such cell responses will improve scientists' understanding of cell pathways and aid in the development of new therapies for many diseases.
NIH/Common Fund, NIH/National Institute of Neurological Disorders and Stroke

Contact: Steven Benowitz
steven.benowitz@nih.gov
301-451-8325
NIH/National Human Genome Research Institute

Public Release: 9-Sep-2014
NIH launches online database of international clinical research regulations
The National Institutes of Health (NIH) today launched ClinRegs, an online public database of country-specific clinical research regulatory information. The ClinRegs website, created and maintained by NIH's National Institute of Allergy and Infectious Diseases, enables users to explore and compare regulations across different countries.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Hillary Hoffman
hillary.hoffman@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 9-Sep-2014
Molecular Psychiatry
Eating habits, body fat related to differences in brain chemistry
People who are obese may be more susceptible to environmental food cues than their lean counterparts due to differences in brain chemistry that make eating more habitual and less rewarding, according to a National Institutes of Health study published in Molecular Psychiatry.
NIH/National Institute of Diabetes and Digestive and Kidney Diseases, NIH/National Institute of Mental Health

Contact: Krysten Carrera
NIDDKMedia@mail.nih.gov
301-496-3583
NIH/National Institute of Diabetes and Digestive and Kidney Diseases

Public Release: 8-Sep-2014
Nature Medicine
Rapid and durable protection against ebola virus with new vaccine regimens
One shot of an experimental vaccine made from two Ebola virus gene segments incorporated into a chimpanzee cold virus vector, called chimp adenovirus type 3 or ChAd3, protected all four macaque monkeys exposed to high levels of Ebola virus 5 weeks after inoculation, report National Institutes of Health scientists and their collaborators.
NIH/National Institute of Allergy and Infectious Diseases

Contact: NIAID Office of Communications
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 3-Sep-2014
Nature
NIH-led scientists discover HIV antibody that binds to novel target on virus
An NIH-led team of scientists has discovered a new vulnerability in the armor of HIV that a vaccine, other preventive regimen or treatment could exploit. The site straddles two proteins, gp41 and gp120, that jut out of the virus and augments other known places where broadly neutralizing antibodies (bNAbs) bind to HIV. This newly identified site on the viral spike is where a new antibody found by the scientists in an HIV-infected person binds to the virus.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Laura S. Leifman
laura.sivitz@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 28-Aug-2014
NIH to Launch human safety study of Ebola vaccine candidate
Initial human testing of an investigational vaccine to prevent Ebola virus disease will begin next week by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The early-stage trial will begin initial human testing of a vaccine co-developed by NIAID and GlaxoSmithKline and will evaluate the experimental vaccine's safety and ability to generate an immune system response in healthy adults. Testing will take place at the NIH Clinical Center in Bethesda, Maryland.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Kathy Stover
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 27-Aug-2014
Nature
Scientists plug into a learning brain
Scientists explored the brain's capacity to learn and found learning is easier when it only requires nerve cells to rearrange existing patterns of activity than when the nerve cells have to generate new patterns.
National Institutes of Health, National Science Foundation, Burroughs Wellcome Fund

Contact: Christopher G. Thomas
thomaschr@ninds.nih.gov
301-496-5751
NIH/National Institute of Neurological Disorders and Stroke

Showing releases 1-25 out of 104.

1 | 2 | 3 | 4 | 5 > >>

     
   

HOME    DISCLAIMER    PRIVACY POLICY    CONTACT US
Copyright ©2014 by AAAS, the science society.